{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:41Z","timestamp":1790681261911,"version":"4.1.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jacl.2015.11.010","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T12:04:38Z","timestamp":1448453078000},"page":"472-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":258,"title":["A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1089-3896","authenticated-orcid":false,"given":"Rishi K.","family":"Wadhera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan L.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnne M.","family":"Foody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.11.010_bib1","unstructured":"World Health Organization: Health statistics and information systems. Cause-specific mortality. Glob Summ estimates for 2000-2012. Available at: http:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates\/en\/index1.html. Accessed January 2, 2015."},{"key":"10.1016\/j.jacl.2015.11.010_bib2","series-title":"Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health","article-title":"Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries","year":"2010"},{"key":"10.1016\/j.jacl.2015.11.010_bib3","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","article-title":"Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"Murray","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib5","series-title":"The Global Economic Burden of Noncommunicable Disease","author":"Bloom","year":"2011"},{"key":"10.1016\/j.jacl.2015.11.010_bib6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","article-title":"Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002","volume":"30","author":"Bjorck","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib8","doi-asserted-by":"crossref","first-page":"d8136","DOI":"10.1136\/bmj.d8136","article-title":"Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study","volume":"344","author":"Bandosz","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2015.11.010_bib9","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2010.580","article-title":"Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005","volume":"303","author":"Wijeysundera","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.recesp.2011.05.033","article-title":"[Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988-2005]","volume":"64","author":"Flores-Mateo","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/2047487312441725","article-title":"Modelling coronary heart disease mortality in Northern Ireland between 1987 and 2007: broader lessons for prevention","volume":"20","author":"Hughes","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib12","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib13","doi-asserted-by":"crossref","first-page":"e13957","DOI":"10.1371\/journal.pone.0013957","article-title":"Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006","volume":"5","author":"Aspelund","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2015.11.010_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2105\/AJPH.2008.147173","article-title":"Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000","volume":"100","author":"Palmieri","year":"2010","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jacl.2015.11.010_bib15","doi-asserted-by":"crossref","first-page":"g1088","DOI":"10.1136\/bmj.g1088","article-title":"Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data","volume":"348","author":"Hotchkiss","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2015.11.010_bib16","doi-asserted-by":"crossref","first-page":"e1001237","DOI":"10.1371\/journal.pmed.1001237","article-title":"Analysing recent socioeconomic trends in coronary heart disease mortality in England, 2000-2007: a population modelling study","volume":"9","author":"Bajekal","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2015.11.010_bib18","first-page":"S1","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.010_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2013full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib21","unstructured":"Feingold KR, Grunfeld C: Introduction to Lipids and Lipoproteins. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et\u00a0al, eds. Endotext. South Dartmouth (MA),\u00a02000."},{"key":"10.1016\/j.jacl.2015.11.010_bib22","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0002-8703(99)70266-8","article-title":"Atherosclerosis is an inflammatory disease","volume":"138","author":"Ross","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1172\/JCI10695","article-title":"Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100","volume":"106","author":"Veniant","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacl.2015.11.010_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/01.CIR.0000054781.50889.0C","article-title":"Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion","volume":"107","author":"Lieu","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2015.11.010_bib28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib29","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease","volume":"371","author":"Stitziel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib30","doi-asserted-by":"crossref","first-page":"e2986","DOI":"10.1371\/journal.pone.0002986","article-title":"Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease\u2013a Mendelian Randomisation study","volume":"3","author":"Linsel-Nitschke","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2015.11.010_bib31","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jacc.2013.12.055","article-title":"The ABCG5\/8 cholesterol transporter and myocardial infarction versus gallstone disease","volume":"63","author":"Stender","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in\u00a0PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib34","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib36","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0904560106","article-title":"Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels","volume":"106","author":"Steinberg","year":"2009","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.jacl.2015.11.010_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib39","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","article-title":"Metabolic origins and clinical significance of LDL heterogeneity","volume":"43","author":"Berneis","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.11.010_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2015.11.010_bib42","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4065\/79.1.101","article-title":"Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer","volume":"79","author":"O'Keefe","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2015.11.010_bib44","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/sj.ejcn.1601353","article-title":"The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic","volume":"56","author":"Cordain","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib45","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pcad.2010.01.003","article-title":"From Framingham to North Karelia: from descriptive epidemiology to public health action","volume":"53","author":"Puska","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.11.010_bib47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ije\/dyp330","article-title":"Thirty-five-year trends in cardiovascular risk factors in Finland","volume":"39","author":"Vartiainen","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3945\/jn.108.095125","article-title":"Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake","volume":"139","author":"Demonty","year":"2009","journal-title":"J Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archinternmed.2010.79","article-title":"Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials","volume":"170","author":"Sabate","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib51","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ajcn\/85.4.1148","article-title":"Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials","volume":"85","author":"Taku","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ajcn\/44.6.788","article-title":"Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic lipoproteins in men","volume":"44","author":"Williams","year":"1986","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11883-005-0062-9","article-title":"Influence of dietary carbohydrate and fat on LDL and HDL particle distributions","volume":"7","author":"Siri","year":"2005","journal-title":"Curr Atheroscler Rep"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2015.11.010_bib54","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib55","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S0007114511003436","article-title":"Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome","volume":"107","author":"Richard","year":"2012","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jacl.2015.11.010_bib56","doi-asserted-by":"crossref","first-page":"A1449","DOI":"10.1016\/S0735-1097(15)61449-8","article-title":"Adherence\u00a0to Mediterranean is the most important protector against the development of fatal and non-fatal cardiovascular event: 10-year follow-up (2002-12) of the Attica study","volume":"65","author":"Georgousopoulou","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0140-6736(90)91656-U","article-title":"Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial","volume":"336","author":"Ornish","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib58","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0735-1097(01)01236-0","article-title":"Exercise training intervention after coronary angioplasty: the ETICA trial","volume":"37","author":"Belardinelli","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.eurheartj.a014966","article-title":"A comparison of the effects of\u00a0strength and aerobic exercise training on exercise capacity and lipids after coronary artery bypass surgery","volume":"17","author":"Wosornu","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0002-9149(02)03159-4","article-title":"Long-term changes in exercise capacity, quality of life, body anthropometry, and lipid profiles after a cardiac rehabilitation program in obese patients with coronary heart disease","volume":"91","author":"Yu","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib61","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM198811033191801","article-title":"Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise","volume":"319","author":"Wood","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0026-0495(97)90300-0","article-title":"Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men","volume":"46","author":"Halle","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2015.11.010_bib63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.ATV.9.5.623","article-title":"Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men","volume":"9","author":"Williams","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacl.2015.11.010_bib64","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2011.08.042","article-title":"Effects of physical activity on cardiovascular disease","volume":"109","author":"Ahmed","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib66","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1161\/CIRCULATIONAHA.105.539106","article-title":"Treatment of elevated cholesterol","volume":"111","author":"Scirica","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib67","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib68","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib70","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib71","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jacl.2015.11.010_bib72","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib73","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib74","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib75","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib76","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib77","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib78","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib80","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2015.11.010_bib81","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a\u00a0prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib82","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib83","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib84","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib85","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib86","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib88","first-page":"1772","article-title":"ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib89","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib90","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib91","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib92","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib93","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib94","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib95","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib96","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMp1112023","article-title":"Needed: pragmatic clinical trials for statin-intolerant patients","volume":"365","author":"Maningat","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib97","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin\u00a0therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib98","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2015.11.010_bib99","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib100","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.010_bib102","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib103","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.amjcard.2013.12.040","article-title":"Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction","volume":"113","author":"Abdallah","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib104","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/CIRCULATIONAHA.113.003589","article-title":"Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction","volume":"129","author":"Arnold","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ahj.2010.12.014","article-title":"Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG)","volume":"161","author":"Javed","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib106","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1345\/aph.1K209","article-title":"Factors related to adherence to statin therapy","volume":"41","author":"McGinnis","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2015.11.010_bib107","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib108","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood\u00a0Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib109","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the\u00a0uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib111","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib112","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib113","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very\u00a0low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib114","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.amjcard.2014.08.041","article-title":"Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg\/dl) With Rosuvastatin 20 mg Daily (from JUPITER)","volume":"114","author":"Everett","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0021-9150(01)00663-3","article-title":"Unique character and metabolism of high density lipoprotein (HDL) in fetus","volume":"161","author":"Nagasaka","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.010_bib116","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000243407","article-title":"Lipids, lipoproteins and apolipoproteins AI, AII, B, CII, CIII and E in newborns","volume":"60","author":"Averna","year":"1991","journal-title":"Biol Neonate"},{"key":"10.1016\/j.jacl.2015.11.010_bib117","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCULATIONAHA.107.753152","article-title":"Evidence mandating earlier and more aggressive treatment of hypercholesterolemia","volume":"118","author":"Steinberg","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib118","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X\u00a0mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.010_bib119","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacl.2015.11.010_bib120","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2013.03.005","article-title":"Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids","volume":"7","author":"Cohen","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib121","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy","volume":"58","author":"Joseph","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.11.010_bib123","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib124","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.tcm.2015.01.009","article-title":"PCSK9 inhibition in patients with hypercholesterolemia","volume":"25","author":"Desai","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib127","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of Proprotein Convertase Subtilisin\/Kexin Type 9 Antibodies in Adults\u00a0With Hypercholesterolemia: A Systematic Review and Meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib128","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-013-0071-8","article-title":"Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective","volume":"52","author":"Mohammadpour","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacl.2015.11.010_bib130","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib131","unstructured":"Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease,\u00a02015. Available at: https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=936130."},{"key":"10.1016\/j.jacl.2015.11.010_bib132","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacl.2014.09.013","article-title":"Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin","volume":"9","author":"Krauss","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib134","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjmed.2012.04.045","article-title":"Targeting preschool children to promote cardiovascular health: cluster randomized trial","volume":"126","author":"Cespedes","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib136","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1161\/CIRCULATIONAHA.105.549857","article-title":"Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002","volume":"112","author":"Arnett","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.010_bib137","first-page":"117","article-title":"Disparities in screening for and awareness of high blood cholesterol\u2013United States, 1999-2002","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jacl.2015.11.010_bib138","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","article-title":"Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction","volume":"62","author":"Arnold","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib139","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","article-title":"Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes","volume":"167","author":"Choudhry","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib141","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2015.11.010_bib142","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2710.2000.00315.x","article-title":"Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients","volume":"25","author":"Kiortsis","year":"2000","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jacl.2015.11.010_bib143","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.amjcard.2003.07.008","article-title":"Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population","volume":"92","author":"Kopjar","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.010_bib144","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2796.1997.112133000.x","article-title":"The problem of compliance to cholesterol altering therapy","volume":"241","author":"Insull","year":"1997","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib146","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archinte.1990.00390160093019","article-title":"The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly","volume":"150","author":"Col","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib147","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1207\/s15324796abm2702_6","article-title":"Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment","volume":"27","author":"Stilley","year":"2004","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib148","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: a cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.010_bib149","first-page":"509","article-title":"The effects of prescription drug copayments on statin adherence","volume":"12","author":"Gibson","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacl.2015.11.010_bib150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.010_bib151","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient\u00a0compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2015.11.010_bib152","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10557-005-5202-5","article-title":"Being well-informed about statin is associated with continuous adherence and reaching targets","volume":"19","author":"Yilmaz","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2015.11.010_bib153","first-page":"CD004371","article-title":"Interventions to improve adherence to lipid lowering medication","author":"Schedlbauer","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2015.11.010_bib154","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ahj.2010.12.019","article-title":"Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects","volume":"161","author":"Muntner","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.010_bib155","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib156","doi-asserted-by":"crossref","first-page":"482","DOI":"10.7326\/0003-4819-157-7-201210020-00004","article-title":"Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus","volume":"157","author":"Reed","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.11.010_bib157","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/193229681300700302","article-title":"Telemedicine diabetes consultations are cost-effective, and effects on essential diabetes treatment parameters are similar to conventional treatment: 7-year results from the Svendborg Telemedicine Diabetes Project","volume":"7","author":"Levin","year":"2013","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.jacl.2015.11.010_bib158","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jacl.2013.10.004","article-title":"Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials","volume":"7","author":"Aspry","year":"2013","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T18:51:10Z","timestamp":1567363870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415004493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":158,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1933287415004493"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 National Lipid Association.","name":"copyright","label":"Copyright"}]}}